These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 19722264)

  • 41. Molecular mechanism of HIV-1 resistance to sifuvirtide, a clinical trial-approved membrane fusion inhibitor.
    Yu D; Ding X; Liu Z; Wu X; Zhu Y; Wei H; Chong H; Cui S; He Y
    J Biol Chem; 2018 Aug; 293(33):12703-12718. PubMed ID: 29929981
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The X-ray structure of RANTES: heparin-derived disaccharides allows the rational design of chemokine inhibitors.
    Shaw JP; Johnson Z; Borlat F; Zwahlen C; Kungl A; Roulin K; Harrenga A; Wells TN; Proudfoot AE
    Structure; 2004 Nov; 12(11):2081-93. PubMed ID: 15530372
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibition of HIV type 1 BaL replication by MIP-1alpha, MIP-1beta, and RANTES in macrophages.
    Capobianchi MR; Abbate I; Antonelli G; Turriziani O; Dolei A; Dianzani F
    AIDS Res Hum Retroviruses; 1998 Feb; 14(3):233-40. PubMed ID: 9491913
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Structural and Functional Characterization of the Secondary Mutation N126K Selected by Various HIV-1 Fusion Inhibitors.
    Yu D; Su Y; Ding X; Zhu Y; Qin B; Chong H; Cui S; He Y
    Viruses; 2020 Mar; 12(3):. PubMed ID: 32197300
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CC chemokine receptor 5-mediated signaling and HIV-1 Co-receptor activity share common structural determinants. Critical residues in the third extracellular loop support HIV-1 fusion.
    Alkhatib G; Ahuja SS; Light D; Mummidi S; Berger EA; Ahuja SK
    J Biol Chem; 1997 Aug; 272(32):19771-6. PubMed ID: 9242636
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication.
    Takashima K; Miyake H; Furuta RA; Fujisawa JI; Iizawa Y; Kanzaki N; Shiraishi M; Okonogi K; Baba M
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3538-43. PubMed ID: 11709336
    [TBL] [Abstract][Full Text] [Related]  

  • 47. LD78beta, a non-allelic variant of human MIP-1alpha (LD78alpha), has enhanced receptor interactions and potent HIV suppressive activity.
    Nibbs RJ; Yang J; Landau NR; Mao JH; Graham GJ
    J Biol Chem; 1999 Jun; 274(25):17478-83. PubMed ID: 10364178
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41.
    Murray EJ; Leaman DP; Pawa N; Perkins H; Pickford C; Perros M; Zwick MB; Butler SL
    J Virol; 2010 Jul; 84(14):7288-99. PubMed ID: 20427524
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
    Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Beta-chemokine inhibition of monocytotropic HIV-1 infection. Interference with a postbinding fusion step.
    Oravecz T; Pall M; Norcross MA
    J Immunol; 1996 Aug; 157(4):1329-32. PubMed ID: 8759710
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The lupane-type triterpene 30-oxo-calenduladiol is a CCR5 antagonist with anti-HIV-1 and anti-chemotactic activities.
    Barroso-González J; El Jaber-Vazdekis N; García-Expósito L; Machado JD; Zárate R; Ravelo ÁG; Estévez-Braun A; Valenzuela-Fernández A
    J Biol Chem; 2009 Jun; 284(24):16609-16620. PubMed ID: 19386595
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Variants of CCR5, which are permissive for HIV-1 infection, show distinct functional responses to CCL3, CCL4 and CCL5.
    Dong HF; Wigmore K; Carrington MN; Dean M; Turpin JA; Howard OM
    Genes Immun; 2005 Oct; 6(7):609-19. PubMed ID: 16015368
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Structural determinants of CCR5 recognition and HIV-1 blockade in RANTES.
    Nardese V; Longhi R; Polo S; Sironi F; Arcelloni C; Paroni R; DeSantis C; Sarmientos P; Rizzi M; Bolognesi M; Pavone V; Lusso P
    Nat Struct Biol; 2001 Jul; 8(7):611-5. PubMed ID: 11427892
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection.
    Proost P; De Meester I; Schols D; Struyf S; Lambeir AM; Wuyts A; Opdenakker G; De Clercq E; Scharpé S; Van Damme J
    J Biol Chem; 1998 Mar; 273(13):7222-7. PubMed ID: 9516414
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil.
    Champagne K; Shishido A; Root MJ
    J Biol Chem; 2009 Feb; 284(6):3619-27. PubMed ID: 19073602
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of CC chemokine receptor 5 (CCR5) inhibitors on the dynamics of CCR5 and CC-chemokine-CCR5 interactions.
    Nakata H; Kruhlak M; Kamata W; Ogata-Aoki H; Li J; Maeda K; Ghosh AK; Mitsuya H
    Antivir Ther; 2010; 15(3):321-31. PubMed ID: 20516552
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A kinetics and modeling study of RANTES(9-68) binding to heparin reveals a mechanism of cooperative oligomerization.
    Vivès RR; Sadir R; Imberty A; Rencurosi A; Lortat-Jacob H
    Biochemistry; 2002 Dec; 41(50):14779-89. PubMed ID: 12475226
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Differential activation of CC chemokine receptors by AOP-RANTES.
    Elsner J; Mack M; Brühl H; Dulkys Y; Kimmig D; Simmons G; Clapham PR; Schlöndorff D; Kapp A; Wells TN; Proudfoot AE
    J Biol Chem; 2000 Mar; 275(11):7787-94. PubMed ID: 10713092
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5.
    Olson WC; Rabut GE; Nagashima KA; Tran DN; Anselma DJ; Monard SP; Segal JP; Thompson DA; Kajumo F; Guo Y; Moore JP; Maddon PJ; Dragic T
    J Virol; 1999 May; 73(5):4145-55. PubMed ID: 10196311
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Donor- and ligand-dependent differences in C-C chemokine receptor 5 reexpression.
    Sabbe R; Picchio GR; Pastore C; Chaloin O; Hartley O; Offord R; Mosier DE
    J Virol; 2001 Jan; 75(2):661-71. PubMed ID: 11134280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.